Bioventure AnGes MG tries again to market Japan’s first gene therapy – Nikkei Asian Review
|
Bioventure AnGes MG tries again to market Japan's first gene therapy
Nikkei Asian Review TOKYO — AnGes MG expects to apply in October for approval to manufacture and market a treatment for severe blockage of the arteries in the legs that could become the first commercial gene therapy product in Japan. The Japanese biopharmaceutical … |
